6550 Stock Overview
Polaris Group provides consulting services to post-acute health care providers in the United States.
Polaris Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$109.00|
|52 Week High||NT$137.50|
|52 Week Low||NT$53.00|
|1 Month Change||-14.84%|
|3 Month Change||41.19%|
|1 Year Change||67.95%|
|3 Year Change||442.29%|
|5 Year Change||336.00%|
|Change since IPO||-1.21%|
Recent News & Updates
|6550||TW Biotechs||TW Market|
Return vs Industry: 6550 exceeded the TW Biotechs industry which returned 9.1% over the past year.
Return vs Market: 6550 exceeded the TW Market which returned 0.7% over the past year.
|6550 Average Weekly Movement||10.7%|
|Biotechs Industry Average Movement||5.3%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.1%|
Stable Share Price: 6550 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 6550's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
Polaris Group provides consulting services to post-acute health care providers in the United States. The company offers medicare consulting services comprising of operations assessment and training and audits. It also offers mock surveys consisting of nursing facility, as well as clinical compliance consulting and infection control services.
Polaris Group Fundamentals Summary
|6550 fundamental statistics|
Is 6550 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6550 income statement (TTM)|
|Cost of Revenue||NT$12.94m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.03|
|Net Profit Margin||-4,923.12%|
How did 6550 perform over the long term?See historical performance and comparison
Is Polaris Group undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6550's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6550's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 6550 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 6550 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6550's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6550 is overvalued based on its PB Ratio (10.9x) compared to the TW Biotechs industry average (3.8x).
How is Polaris Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Polaris Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Polaris Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6550 is currently unprofitable.
Growing Profit Margin: 6550 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6550 is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.
Accelerating Growth: Unable to compare 6550's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6550 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).
Return on Equity
High ROE: 6550 has a negative Return on Equity (-10.26%), as it is currently unprofitable.
How is Polaris Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6550's short term assets (NT$6.3B) exceed its short term liabilities (NT$436.8M).
Long Term Liabilities: 6550's short term assets (NT$6.3B) exceed its long term liabilities (NT$171.5M).
Debt to Equity History and Analysis
Debt Level: 6550 has more cash than its total debt.
Reducing Debt: 6550's debt to equity ratio has reduced from 701.7% to 5.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6550 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6550 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 15.7% each year
What is Polaris Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6550's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6550's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6550's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6550's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6550 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Polaris Group has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.
Polaris Group's employee growth, exchange listings and data sources
- Name: Polaris Group
- Ticker: 6550
- Exchange: TPEX
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$78.354b
- Shares outstanding: 718.85m
- Website: https://www.polaris-group.com
- Polaris Group
- 3030 North Rocky Point Drive
- Suite 240
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.